GSA Capital Partners’s Arbutus Biopharma ABUS Stock Holding History

GSA Capital Partners’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$212K	Buy	+44,082	New	+$194K	0.01%	1493
2023 Q3	–	Sell	-36,923	Closed	-$85K	–	1443
2023 Q2	$85K	Sell	36,923 -1,237	-3%	-$3.22K	0.01%	1391
2023 Q1	$116K	Sell	38,160 -79,031	-67%	-$223K	0.01%	1337
2022 Q4	$273K	Buy	117,191 +22,391	+24%	+$53.6K	0.03%	999
2022 Q3	$181K	Buy	94,800 +78,664	+488%	+$185K	0.02%	1258
2022 Q2	$44K	Sell	16,136 -16,317	-50%	-$41.8K	0.01%	1297
2022 Q1	$97K	Buy	+32,453	New	+$99.3K	0.01%	1298
2021 Q2	–	Sell	-309,839	Closed	-$1.03M	–	1285
2021 Q1	$1.03M	Buy	309,839 +283,618	+1,082%	+$1.09M	0.17%	125
2020 Q4	$93K	Buy	+26,221	New	+$91.8K	0.02%	1103

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GSA Capital Partners's ABUS Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 44,082 shares worth $212K. The stake represents 0.01% of the portfolio and ranks #1493 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in ABUS as recently as Q2 2023.

GSA Capital Partners first reported a position in ABUS in Q4 2020 and has held it in 9 quarters since. The position peaked at $1.03M in Q1 2021. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

GSA Capital Partners held 44,082 shares of Arbutus Biopharma worth $212K as of Q2 2026.
Arbutus Biopharma was a new GSA Capital Partners position in Q2 2026.
Arbutus Biopharma made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1493 holding.
GSA Capital Partners first reported a position in Arbutus Biopharma in Q4 2020 and has held it in 9 quarters since.
GSA Capital Partners's Arbutus Biopharma position peaked at $1.03M in Q1 2021.
176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.